Gene therapy approaches for Hemophilia A and B
Moataz Dowaidar
Abstract
The increasing number of approved gene therapy drugs and the impending licensing of AAV-based gene transfer drugs for Hemophilia A (HA) and hemophilia B (HB) has prompted optimism that equivalent therapeutics for other monogenic bleeding illnesses may be established. Although the benefits of replacement therapies have proven the case for gene therapy of other rare hereditary bleeding disorders, translational gene therapy for these diseases will almost definitely require additional breakthroughs. AAV vector safety in human volunteers was first demonstrated in FIX gene transfer skeletal-muscle-directed investigations. FVII, VWD and GT gene therapy may require comparable breakthroughs to overcome present restrictions. Alloantibodies are present in all hereditary bleeding disorders.A growing body of research indicates AAV gene therapy, especially liver-directed approaches, may be more tolerogenic than protein therapy. Better awareness of variances in transgene expression in male and female participants following AAV liver-directed gene therapy would be critical for autosomal disorders. The mutant transgenes FVIII-BDD and FIX-Padua. respectively considerably assisted gene therapy forHA and HB. The effects of systemically administered SMA in infants were examined. Similarly, the effects of the systemically administered SMA in infants on infants were examined. The effects on hemostatic efficacy due to decreased multimerization. The gene therapy product uniQure NV (Amsterdam, The Netherlands), efficiently replaced FIX-WT with projected improvements in FIX activity levels and without restarting clinical development. With projected high costs of gene therapy, new quality-of-life data is needed to better understand the cost-benefit of such therapies.